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Abstract
From a technical perspective, there are fundamentally two forces driving the evolution
of instrumentation in positron emission tomography (PET) and nuclear medicine
generally: clinical needs and technical innovation. This essay considers some of the
dynamics of these forces as they act on physics-related developments in PET and
suggests that progress will be greatest if these differing motivations are kept in balance
as the field evolves.
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Background
In the context of positron emission tomography (PET), and nuclear medicine generally,
the term ‘physics’ has come to refer to far more than just the underlying physical princi-
ples of the generation, transport, and detection of nuclear radiation; it encompasses many
aspects of the delivery and uptake of radioactive tracers, instrumentation design, signal
processing, data corrections, image reconstruction, and quantitative analysis. The scope
of the historical and future development of this field, as eloquently laid out in the four
inaugural papers in this journal [1-4], is truly remarkable and challenging to comprehend
fully. In trying to understand the dynamics that govern this development, I find it helpful
to analyze them in terms of two motivating forces that these authors have described: the
needs of clinical applications and the possibilities of technical innovations. These are, of
course, just the endpoints of the spectrum of scientific motivations for change in nuclear
medical physics, and most advances will be influenced to a greater or lesser extent by
both.
Main text
Clinically driven development is that which is motivated primarily by the desire to satisfy
a specific clinical need for which no adequate solution currently exists. The introduc-
tion of multi-bed, whole-body imaging, for example, addressed the issue of diagnosing
the metastatic spread of cancer [5]. The initial implementations of attenuation, scatter,
and prompt-gamma corrections in PET responded to the need for quantitation of tracer
uptake. The development of specialized systems for breast and prostate cancer imaging
and high-resolution head scanners for neurological studies are all examples of such clin-
ically motivated progress. Recently, the advent of tracers enabling beta-amyloid plaque
imaging in the brain has sparked the implementation of new attenuation correction
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and image analysis techniques designed specifically to support screening for Alzheimer’s
Disease [6].
Physics-driven development, on the other hand, is that which is motivated more by
the desire to improve the technology or performance of an imaging (or other) system
in general rather than to achieve a specific clinical goal, although it is nevertheless ulti-
mately justified by the value it brings to established clinical applications or novel ones
that it enables. The transition from 2D (with inter-plane septa) to 3D (without septa)
PET imaging in the 1990s, for example, involved a long process of trying to understand
the benefits of 3D and optimize its performance in general-purpose whole-body scanners
[7]. This optimization was frequently based on a physical rather than a clinically derived
metric [8]. Similarly, the introductions of LSO/LYSO scintillators, iterative reconstruc-
tion algorithms, and time-of-flight (TOF) measurement were all motivated by the desire
to improve imaging performance generally. Today, we are witnessing the first wave of a
similarly important technological advance: the replacement of conventional photomulti-
plier tubes with solid-state photomultipliers, which holds great promise to reduce the size
and increase the performance of PET scanners [9,10].
A distinctive characteristic of physics-driven innovation is that it tends to be more risky
than clinically driven development; its value may not be as obvious from the outset. As
hard as it may be to believe today, the development and introduction of PET/CT was
slowed by the considerable initial skepticism with which the concept was met. Equip-
ment manufacturers were unsure at first of its commercial potential and hesitant to invest
heavily in it. Many in nuclear medicine doubted its clinical utility and cost effective-
ness. It was not until the value of the fused PET and CT images and superiority of the
CT-based attenuation correction became obvious from actual clinical use that the land-
slide of its adoption began. The PET/MR is arguably an even more technically and
clinically complex system than PET/CT, and thus, one whose ultimate clinical value is
even more difficult to foresee. Sometimes, technologies simply fail to meet expectations,
such as the ‘wobble’ feature on many early PET gantries designed to improve spatial res-
olution, but whose benefits were eventually judged not worth the inherent problems of
increased complexity and noise, and reducedmechanical reliability. A hybrid PET/SPECT
system [11] developed in the late 1990s, with innovative LSO/NaI phoswich detectors
and novel coincidence point source transmission capability, never took off clinically due
partly to the fact that compelling applications for it never emerged.
On the other hand, it’s important to recognize that even when a new physics-driven
development fails to be widely adopted clinically, it may still lead to important advances.
The first prototype of the PET/CT that provided proof-of-principle data was inspired
by, and constructed from, technology and components developed for an innovative
partial-ring rotating tomograph that itself never made the commercial mainstream [12].
Likewise, the first incarnation of time-of-flight (TOF) PET based on CsF and BaF2 detec-
tors ultimately failed in its competition with more sensitive BGO-based systems. Yet, the
extensive research and development of TOF for these early systems laid a solid founda-
tion for its rapid adoption once enabling LSO/LYSO detector technology matured and
became widely available [13].
Another important aspect of the dynamics of PET physics is the synergism between
technologies developed more or less independently that can lead to unanticipated
advances. An interesting example is that of attenuation correction (AC). Prior to PET/CT,
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AC was based almost exclusively on transmission measurements made with radioac-
tive sources. With the advent of CT-based AC, such techniques became obsolete.
Recently, however, there has been renewed interest in transmission measurements due
to several complimentary developments: New joint emission-attenuation reconstruction
algorithms permit extraction of a great deal of attenuation information from emission-
only [14,15] or simultaneous emission-transmission [16] data. Positron beams offer a
mechanically simple means for injecting transmission sources into the field of view of
integrated PET/MR systems [16]. TOF measurements allow useful discrimination of
emission and transmission data in simultaneous scans [17]. Furthermore, it has been
increasingly realized that the needed AC information may be derived from multiple
sources used together: emission data, partial transmission data, and segmented MR
images, for example [15,16]. Such combinations of technologies open up new possibilities
not envisioned a decade ago. This type of synergistic advance seems more likely to occur
in the context of physics-driven developments than in clinically driven ones.
Conclusions
From my perspective in commercial PET development, it seems that the history of PET
cameras over the past 20 years has largely been driven by efforts to make better images
of [18F]-fluoro-deoxy-glucose (FDG). Because the clinical target was so slowly moving, it
provided a great opportunity for optimizing the physics of this part of PET. But perhaps, it
could be said that as a consequence, we in the medical imaging community did not spend
our resources as well as we might have to bring progress to PET or nuclear medicine as
a whole. The picture of the future painted in the inaugural papers in this journal [1,4] is
quite different: FDG’s role will diminish, and we will see the evolution of nuclear medicine
become increasingly driven by the clinical need to provide ever more sensitive and precise
techniques to characterize and influence the molecular biology of disease in a variety of
new and different ways, using an increasing array of biomarkers, multi-parametric meth-
ods, and radionuclide therapies. This will undoubtedly be a healthy development for the
field; but at the same time, I think it is important to keep in mind that PET and other
nuclear medical technologies are still very far from achieving their full technical potential.
Tremendous fundamental advances in time, energy, and spatial resolutions; sensitivity;
data corrections; reconstruction; and information extraction still remain to be realized
[1,4]. As we make the transition to a future of more varied and demanding clinical appli-
cations, it will be important to maintain a proper balance between the contributions from
clinically oriented physics research (in the broadest sense of this term) on one side of the
spectrum, and the technology-oriented physics research on the other. Clearly, we need
to focus on the more promising new clinical applications to guide us in the most effi-
cient use of our resources, but it would be unfortunate if in doing this we under-invested
in the type of non-application-specific, physics-driven, technological innovations, which,
though sometimes risky, have often proven highly rewarding.
One requisite for achieving such balance is efficient communication about new require-
ments and potential solutions among those working across the spectrum. This will be
challenging, but I am hopeful that this new physics-focused, open-access journal will play
a very useful role in advancing that goal.
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